Phase I trial of docetaxel and short infusion Gemcitabine given every two weeks for advanced solid tumors

被引：0
|
作者：
Davis, TH
Rigas, JR
Maurer, LH
Pipas, JM
Obrocea, M
Tretter, CP
Smith, EL
Meyer, L
Hammond, S
机构：
[1] Norris Cotton Canc Ctr, Lebanon, NH USA
[2] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
642P
引用
收藏
页码：134 / 134
页数：1
相关论文
共 50 条
  • [41] A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors
    Schelman, William
    Morgan-Meadows, Sherry
    Bailey, Howard
    Holen, Kyle
    Thomas, James P.
    Eickhoff, Jens
    Brandon, Heidi
    Oliver, Kate
    Alberti, Dona
    Wilding, George
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (04) : 727 - 733
  • [42] Phase I clinical and pharmacologic study of docetaxel and gemcitabine in patients with advanced solid tumors; a novel two week schedule
    Obrocea, M
    Davis, TH
    Lewis, LD
    Maurer, LH
    Pipas, JM
    Smith, EL
    Meyer, LP
    Hammond, S
    Rigas, JR
    ANNALS OF ONCOLOGY, 1998, 9 : 95 - 95
  • [43] Phase I study of men-10755 in patients with a solid tumor as a short i.v. infusion given once every 3 weeks
    Roelvink, M
    Aamdal, S
    Dombernowsky, P
    Wanders, J
    Peters, S
    Bortini, S
    Crea, A
    Animati, A
    Hanauske, AR
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S289 - S289
  • [44] Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors
    Wakelee, H. A.
    Patnaik, A.
    Sikic, B. I.
    Mita, M.
    Fox, N. L.
    Miceli, R.
    Ullrich, S. J.
    Fisher, G. A.
    Tolcher, A. W.
    ANNALS OF ONCOLOGY, 2010, 21 (02) : 376 - 381
  • [45] Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors
    Maurel, J
    Zorrilla, M
    Puertolas, T
    Antón, A
    Herrero, A
    Artal, A
    Alonso, V
    Martinez-Trufero, J
    Puertas, MD
    ANTI-CANCER DRUGS, 2001, 12 (09) : 713 - 717
  • [46] Phase I study of XMT-1001, a novel water soluble camptothecin conjugate, given as an intravenous infusion once every three weeks to patients with advanced solid tumors
    Sausville, Edward A.
    Garbo, Lawrence
    Weiss, Glen J.
    Shkolny, Dana
    Yurkovetskiy, Alexander V.
    Bethune, Claudette
    Ramanathan, Ramesh K.
    Fram, Robert J.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [47] A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors
    Ryan, DP
    Lynch, TJ
    Grossbard, ML
    Seiden, MV
    Fuchs, CS
    Grenon, N
    Baccala, P
    Berg, D
    Finkelstein, D
    Mayer, RJ
    Clark, JW
    CANCER, 2000, 88 (01) : 180 - 185
  • [48] Phase I trial of weekly and every-three-weeks ixabepilone (Ix) and sunitinib (S) in advanced solid tumors (STs).
    Amado, V. D. Guardiola
    Montero, A. J.
    Ferrell, A.
    Flores, A. M.
    Vulfovich, M.
    Pegram, M. D.
    Benedetto, P. W.
    Lima, C. S. Rocha
    Merchan, J. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [49] A phase I trial of weekly gemcitabine (GEM), administered as a constant dose-rate infusion, and docetaxel (DOC) in patients with advanced solid tumors (LOA-8).
    Rinaldi, DA
    Lormand, NA
    Rainey, JM
    Brierre, JE
    Cole, JL
    Roden, KB
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 149S - 149S
  • [50] A phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors
    Rademaker-Lakhai, JM
    Terret, C
    Howell, SB
    Baud, CM
    de Boer, RF
    Pluim, D
    Beijnen, JH
    Schellens, JHM
    Droz, JP
    CLINICAL CANCER RESEARCH, 2004, 10 (10) : 3386 - 3395
12345